FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886597817> ?p ?o ?g. }

• W2886597817 endingPage "689" @default.
• W2886597817 startingPage "680" @default.
• W2886597817 abstract "Background and Aims Endoscopic resection (ER) is safe and effective for Barrett’s esophagus (BE) containing high-grade dysplasia (HGD) or mucosal adenocarcinoma (T1A). The risk of metachronous neoplasia is reduced by ablation of residual BE by using radiofrequency ablation (RFA) or argon plasma coagulation (APC). These have not been compared directly. We aimed to recruit up to 100 patients with BE and HGD or T1A confirmed by ER over 1 year in 6 centers in a randomized pilot study. Methods Randomization was 1:1 to RFA or APC (4 treatments allowed at 2-month intervals). Recruitment, retention, dysplasia clearance, clearance of benign BE, adverse events, healthcare costs, and quality of life by using EQ-5D, EORTC QLQ-C30, or OES18 were assessed up to the end of the trial at 12 months. Results Of 171 patients screened, 76 were randomized to RFA (n = 36) or APC (n = 40). The mean age was 69.7 years, and 82% were male. BE was <5 cm (n = 27), 5 to 10 cm (n = 45), and >10 cm (n = 4). Sixty-five patients completed the trial. At 12 months, dysplasia clearance was RFA 79.4% and APC 83.8% (odds ratio [OR] 0.7; 95% confidence interval [CI], 0.2-2.6); BE clearance was RFA 55.8%, and APC 48.3% (OR 1.4; 95% CI, 0.5-3.6). A total of 6.1% (RFA) and 13.3% (APC) had buried BE glands. Adverse events (including stricture rate after starting RFA 3/36 [8.3%] and APC 3/37 [8.1%]) and quality of life scores were similar, but RFA cost $27491 more per case than APC. Conclusion This pilot study suggests similar efficacy and safety but a cost difference favoring APC. A fully powered non-inferiority trial is appropriate to confirm these findings. (Clinical trial registration number: NCT01733719.) Endoscopic resection (ER) is safe and effective for Barrett’s esophagus (BE) containing high-grade dysplasia (HGD) or mucosal adenocarcinoma (T1A). The risk of metachronous neoplasia is reduced by ablation of residual BE by using radiofrequency ablation (RFA) or argon plasma coagulation (APC). These have not been compared directly. We aimed to recruit up to 100 patients with BE and HGD or T1A confirmed by ER over 1 year in 6 centers in a randomized pilot study. Randomization was 1:1 to RFA or APC (4 treatments allowed at 2-month intervals). Recruitment, retention, dysplasia clearance, clearance of benign BE, adverse events, healthcare costs, and quality of life by using EQ-5D, EORTC QLQ-C30, or OES18 were assessed up to the end of the trial at 12 months. Of 171 patients screened, 76 were randomized to RFA (n = 36) or APC (n = 40). The mean age was 69.7 years, and 82% were male. BE was <5 cm (n = 27), 5 to 10 cm (n = 45), and >10 cm (n = 4). Sixty-five patients completed the trial. At 12 months, dysplasia clearance was RFA 79.4% and APC 83.8% (odds ratio [OR] 0.7; 95% confidence interval [CI], 0.2-2.6); BE clearance was RFA 55.8%, and APC 48.3% (OR 1.4; 95% CI, 0.5-3.6). A total of 6.1% (RFA) and 13.3% (APC) had buried BE glands. Adverse events (including stricture rate after starting RFA 3/36 [8.3%] and APC 3/37 [8.1%]) and quality of life scores were similar, but RFA cost $27491 more per case than APC. This pilot study suggests similar efficacy and safety but a cost difference favoring APC. A fully powered non-inferiority trial is appropriate to confirm these findings. (Clinical trial registration number: NCT01733719.)" @default.
• W2886597817 created "2018-08-22" @default.
• W2886597817 creator A5000353679 @default.
• W2886597817 creator A5007597546 @default.
• W2886597817 creator A5013078260 @default.
• W2886597817 creator A5025950669 @default.
• W2886597817 creator A5028099883 @default.
• W2886597817 creator A5029058151 @default.
• W2886597817 creator A5029560991 @default.
• W2886597817 creator A5042695837 @default.
• W2886597817 creator A5048845675 @default.
• W2886597817 creator A5063894822 @default.
• W2886597817 creator A5067114338 @default.
• W2886597817 creator A5081395677 @default.
• W2886597817 date "2019-04-01" @default.
• W2886597817 modified "2023-10-16" @default.
• W2886597817 title "Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or stage T1 adenocarcinoma in Barrett’s esophagus: a randomized pilot study (BRIDE)" @default.
• W2886597817 cites W1907383015 @default.
• W2886597817 cites W1965646632 @default.
• W2886597817 cites W1970359463 @default.
• W2886597817 cites W1973240828 @default.
• W2886597817 cites W1977694803 @default.
• W2886597817 cites W1978483982 @default.
• W2886597817 cites W1984060133 @default.
• W2886597817 cites W1984077508 @default.
• W2886597817 cites W2001439177 @default.
• W2886597817 cites W2001891043 @default.
• W2886597817 cites W2004071307 @default.
• W2886597817 cites W2004669541 @default.
• W2886597817 cites W2005251899 @default.
• W2886597817 cites W2005982125 @default.
• W2886597817 cites W2009853481 @default.
• W2886597817 cites W2015535757 @default.
• W2886597817 cites W2027101401 @default.
• W2886597817 cites W2045897609 @default.
• W2886597817 cites W2052478842 @default.
• W2886597817 cites W2059338543 @default.
• W2886597817 cites W2068605435 @default.
• W2886597817 cites W2071916185 @default.
• W2886597817 cites W2073163566 @default.
• W2886597817 cites W2080559672 @default.
• W2886597817 cites W2087214005 @default.
• W2886597817 cites W2100446918 @default.
• W2886597817 cites W2102632921 @default.
• W2886597817 cites W2107225782 @default.
• W2886597817 cites W2118930975 @default.
• W2886597817 cites W2120450267 @default.
• W2886597817 cites W2125681184 @default.
• W2886597817 cites W2132297193 @default.
• W2886597817 cites W2133540202 @default.
• W2886597817 cites W2141147516 @default.
• W2886597817 cites W2147556962 @default.
• W2886597817 cites W2151288871 @default.
• W2886597817 cites W2159594443 @default.
• W2886597817 cites W2161840081 @default.
• W2886597817 cites W2167571044 @default.
• W2886597817 cites W2167806660 @default.
• W2886597817 cites W2171715366 @default.
• W2886597817 cites W2442144486 @default.
• W2886597817 cites W2473786944 @default.
• W2886597817 cites W2620708848 @default.
• W2886597817 cites W3149306952 @default.
• W2886597817 cites W801636084 @default.
• W2886597817 doi "https://doi.org/10.1016/j.gie.2018.07.031" @default.
• W2886597817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30076843" @default.
• W2886597817 hasPublicationYear "2019" @default.
• W2886597817 type Work @default.
• W2886597817 sameAs 2886597817 @default.
• W2886597817 citedByCount "47" @default.
• W2886597817 countsByYear W28865978172019 @default.
• W2886597817 countsByYear W28865978172020 @default.
• W2886597817 countsByYear W28865978172021 @default.
• W2886597817 countsByYear W28865978172022 @default.
• W2886597817 countsByYear W28865978172023 @default.
• W2886597817 crossrefType "journal-article" @default.
• W2886597817 hasAuthorship W2886597817A5000353679 @default.
• W2886597817 hasAuthorship W2886597817A5007597546 @default.
• W2886597817 hasAuthorship W2886597817A5013078260 @default.
• W2886597817 hasAuthorship W2886597817A5025950669 @default.
• W2886597817 hasAuthorship W2886597817A5028099883 @default.
• W2886597817 hasAuthorship W2886597817A5029058151 @default.
• W2886597817 hasAuthorship W2886597817A5029560991 @default.
• W2886597817 hasAuthorship W2886597817A5042695837 @default.
• W2886597817 hasAuthorship W2886597817A5048845675 @default.
• W2886597817 hasAuthorship W2886597817A5063894822 @default.
• W2886597817 hasAuthorship W2886597817A5067114338 @default.
• W2886597817 hasAuthorship W2886597817A5081395677 @default.
• W2886597817 hasBestOaLocation W28865978172 @default.
• W2886597817 hasConcept C121608353 @default.
• W2886597817 hasConcept C126322002 @default.
• W2886597817 hasConcept C141071460 @default.
• W2886597817 hasConcept C156957248 @default.
• W2886597817 hasConcept C168563851 @default.
• W2886597817 hasConcept C197934379 @default.
• W2886597817 hasConcept C2775894508 @default.
• W2886597817 hasConcept C2777377203 @default.
• W2886597817 hasConcept C2777819096 @default.
• W2886597817 hasConcept C2778451229 @default.

• next